Literature DB >> 7733906

Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells.

C B Srikant1.   

Abstract

Somatostatin (SS) and its analogs exert direct antiproliferative effects in a variety of tumor cells not only by inhibiting the mitogenic signalling of growth factor receptor kinases, but also by inducing apoptosis. In this study, the apoptotic effect of the octreotide SS analog, SMS 201-995, was investigated in phase synchronized AtT-20 mouse pituitary tumor cells. SMS 201-995 added to cells synchronized in G1 or in G2 phases induces apoptosis which is manifested in the subsequent cell cycle. No evidence of apoptosis was seen in cells subjected to cell cycle arrest in G1 by lovastatin or in G2 with 160 nM staurosporine. SMS 201-995 did not induce detectable apoptosis in unsynchronized cells which remained predominantly in G1 phase. These findings provide the first documentation that SS peptides regulate cell growth in G2 to induce apoptosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7733906     DOI: 10.1006/bbrc.1995.1517

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

Review 1.  Endocrine/paracrine control of pituitary cell proliferation and its involvement in pituitary tumorigenesis.

Authors:  M Pawlikowski
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

2.  Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics.

Authors:  J Clay Callison; Ronald C Walker; Pierre P Massion
Journal:  J Lung Cancer       Date:  2011

Review 3.  Neurogenesis and neuronal regeneration in the adult fish brain.

Authors:  G K H Zupanc
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2006-02-07       Impact factor: 1.836

4.  A rare case and a rapid tumor response to therapy: dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma.

Authors:  Cihangir Erem; Arif Hacihasanoglu; Ahmet Sari; Halil Onder Ersöz; Kubilay Ukinç; Sami Fidan
Journal:  Endocrine       Date:  2004-11       Impact factor: 3.633

Review 5.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

6.  Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists.

Authors:  Derun Li; Zhicai Wu; Yang Yu; Richard G Ball; Liangqin Guo; Edward Sherer; Shuwen He; Qingmei Hong; Zhong Lai; Hongbo Qi; Quang Truong; David X Yang; Gary G Chicchi; Kwei-Lan Tsao; Dorina Trusca; Maria Trujillo; Michele Pachanski; George J Eiermann; Andrew D Howard; Yun-Ping Zhou; Bei B Zhang; Ravi P Nargund; William K Hagmann
Journal:  ACS Med Chem Lett       Date:  2014-04-24       Impact factor: 4.345

7.  A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity.

Authors:  G Kéri; J Erchegyi; A Horváth; I Mezõ; M Idei; T Vántus; A Balogh; Z Vadász; G Bökönyi; J Seprõdi; I Teplán; O Csuka; M Tejeda; D Gaál; Z Szegedi; B Szende; C Roze; H Kalthoff; A Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

8.  TSH-secreting pituitary macroadenoma: rapid tumor shrinkage and recovery from hyperthyroidism with octreotide.

Authors:  M P Fischler; W H Reinhart
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

9.  Correlation of bcl-2 and bax with apoptosis in human pituitary adenomas.

Authors:  Demetrios Sambaziotis; Nikiforos Kapranos; George Kontogeorgos
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 10.  Somatostatin and somatostatin receptor physiology.

Authors:  Philip Barnett
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.